Description
This retrospective cohort secondary data analysis aims to evaluate the diagnostic and prognostic utility of positron emission tomography (PET) using the flurpiridaz F-18 (FPZ) radiotracer in patients with known or suspected cardiovascular disease (CVD). The study will analyze data from all patients referred to the Methodist DeBakey Heart & Vascular Center (MDHVC) PET Laboratory who underwent clinically indicated FPZ PET/CT imaging beginning February 2025. Approximately 500 patients will be included.
